BioNTech plans mega takeover of CureVac: future of cancer medicine!

BioNTech plans mega takeover of CureVac: future of cancer medicine!

BioNTech SE announced today that it has completed the acquisition of CureVac N.V. plans. This strategic decision is viewed as an important step in BioNTech's oncology strategy to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapies. BioNTech is in the process of acquiring all shares of CureVac and has announced a public exchange offer for all CureVac shares. The purchase price for each CureVac share is approximately $5.46, for a total valuation of approximately $1.25 billion.

BioNTech is offering CureVac shareholders a 55% premium over the last three months' weighted average price, which was about $3.53. This was unanimously approved by the boards of directors of both companies and is subject to customary closing conditions, including a minimum acceptance threshold of 80% of CureVac shares. Certain CureVac shareholders, holding a total of 36.76% of the shares, have already committed to offering their shares in exchange.

Goals and integration

The main reason for the acquisition is to acquire know-how in the field of mRNA technology, particularly for future cancer therapies. BioNTech founder Ugur Sahin described this acquisition as a significant investment in the future of cancer medicine. CureVac's research location in Tübingen will be retained, and BioNTech plans to prepare an integration plan to integrate CureVac's research and production locations into its own structures.

Additionally, CureVac shareholders are expected to own between 4% and 6% of BioNTech upon completion of the transaction. BioNTech has over 15.9 billion euros in cash and securities investments as of March 31, 2025 and is therefore in a position to finance this acquisition.

Support and outlook

The takeover is supported by CureVac's main shareholder, dievini Hopp BioTech holding GmbH & Co. KG, and viewed positively by the German federal government. BioNTech also expects support from Kreditanstalt für Wiederaufbau, which holds 13.32% of CureVac shares. Both companies aim to create long-term value for their shareholders through this transaction and to fully exploit the possibilities of mRNA technology.

Overall, the takeover is expected to be completed by the end of 2025, depending on the approval of the antitrust authorities and the fulfillment of the agreed conditions. Not only does this represent a significant development for BioNTech, but it could also revolutionize the landscape of cancer research and treatment.

While BioNTech was previously in direct competition with CureVac in the field of corona vaccine development, this relationship is now being transformed into a new context to promote innovative therapies in the fight against cancer. The takeover could be a decisive turning point for the entire industry.

daily news reports that BioNTech plans to acquire CureVac. GlobeNewswire describes the details of this strategic transaction, which could have far-reaching implications for mRNA-based medicine.